The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Pfizer, Moderna File Updated COVID-19 Vaccines in Japan
Pfizer and Moderna have filed applications seeking Japanese regulatory approval for updated monovalent versions of their respective COVID-19 vaccines, both targeting the XBB.1.5 Omicron subvariant, the companies said on July 7. For Pfizer, the updated jab, developed jointly with BioNTech,…
To read the full story
Related Article
- Japan to Buy 10 Million More Doses of Pfizer/Moderna COVID Jabs
October 19, 2023
- Japan Agrees to Buy Extra 10 Million Doses of Pfizer COVID Vaccine
September 27, 2023
- Japan Launches Fall COVID-19 Vaccination Campaign
September 21, 2023
- Moderna’s Omicron XBB.1.5 Vaccine Snags Japan Approval
September 12, 2023
- Japan Panel OKs Use of Pfizer’s XBB.1.5 Jab for Fall Vaccination Campaign
September 11, 2023
- Japan Approves Pfizer’s Omicron XBB.1.5 Vaccine, Moderna’s Still under Review
September 4, 2023
- Moderna Japan’s XBB-Based COVID Jab Actually Filed for Age 6 and Up
August 3, 2023
- Japan to Buy 20 Million Doses of Pfizer COVID Jab, 5 Million from Moderna
July 28, 2023
- Japan Likely to Slash Moderna Vaccine Purchase, Pfizer Single-Sourcing Plan Nixed
July 28, 2023
BUSINESS
- Cyto-Facto Expands CPC Footprint to Win Multiple Cell Therapy Contracts
December 24, 2025
- Shionogi, Salubritas Tie Up on Hair Cell Regeneration R&D for Hearing Loss
December 24, 2025
- Guardant360 Approved in Japan as CDx for Lilly’s Inluriyo
December 24, 2025
- Meiji Pharma Sets Up Singapore Unit to Bolster ASEAN Push
December 24, 2025
- Santen Releases VKC Eye Drop Verkazia in China
December 24, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…